Fact Check: The Reality of Weight Regain After Stopping Weight Loss Medications

Americans turning to weight loss drugs like Ozempic, Wegovy and Mounjaro have been reporting dramatic success stories, but questions remain about what happens when patients stop taking them. Many users are now experiencing a phenomenon commonly called “Ozempic rebound,” where they regain significant weight after discontinuing the medication.

Health experts confirm that weight regain is a common occurrence when patients stop taking GLP-1 receptor agonists, the class of drugs that includes these popular medications. Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, explains that these medications were designed for long-term management, not as short-term solutions.

“These medications were never intended to be taken for a short period,” Stanford said. “Obesity is a chronic disease that requires chronic treatment, similar to how we approach other conditions like diabetes or hypertension.”

The medications work by mimicking hormones that regulate appetite and insulin production, helping patients feel fuller longer and reducing food cravings. When patients discontinue the medication, these biological mechanisms are no longer supported, often leading to increased appetite and subsequent weight gain.

A landmark clinical trial published in the Journal of the American Medical Association found that patients who stopped taking semaglutide (the active ingredient in Wegovy and Ozempic) regained two-thirds of their lost weight within one year of discontinuation. The study tracked 327 adults who had lost an average of 17.3% of their body weight while taking the medication.

Social media platforms are filled with accounts from former users describing rapid weight gain after stopping the medications. Jessica Thompson, a 42-year-old from Atlanta who lost 48 pounds on Ozempic, shared her experience: “Within three months of stopping, I had regained almost all the weight I lost, despite maintaining the same diet and exercise routine I had while on the medication.”

The medications’ high cost—often exceeding $1,000 per month when not covered by insurance—and supply shortages have forced many patients to discontinue treatment prematurely. Insurance coverage remains inconsistent, with many plans classifying these drugs as “lifestyle medications” rather than treatments for a chronic disease.

Medical professionals are increasingly advocating for obesity to be treated as a chronic condition requiring ongoing management. Dr. Ania Jastreboff, director of the Yale Obesity Research Center, emphasizes that the physiological changes that occur with weight loss trigger the body to defend against what it perceives as starvation.

“When someone loses weight, the body interprets this as a threat to survival and activates multiple mechanisms to regain that weight,” Jastreboff explained. “These medications help counteract those biological responses, but once discontinued, those protective mechanisms assert themselves again.”

Some healthcare providers are now recommending a more gradual tapering approach when patients need to stop the medication, rather than abrupt discontinuation. This strategy may help mitigate some of the rebound effect, though research on optimal discontinuation protocols remains limited.

Experts also stress the importance of combining medication with sustainable lifestyle changes. Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, notes that patients who maintain consistent physical activity and dietary habits typically experience less dramatic weight regain.

“The medication gives patients a biological advantage, but building healthy habits during treatment can help sustain some benefits even if the medication is discontinued,” Aronne said.

Pharmaceutical companies Novo Nordisk and Eli Lilly, manufacturers of these medications, acknowledge in their prescribing information that weight regain is expected when treatment ends. Both companies are conducting ongoing studies to better understand long-term outcomes and potential maintenance strategies.

As these medications continue to transform obesity treatment, healthcare systems are grappling with questions about sustainable access and coverage. Obesity specialists increasingly view these medications as tools for chronic disease management rather than temporary interventions, suggesting that long-term or indefinite use may be necessary for many patients to maintain their results.

For patients considering these medications, experts recommend discussing realistic expectations and treatment duration with healthcare providers before starting therapy, and developing strategies for long-term management of their weight and overall health.